Soon, all life-saving drugs may become affordable

Parliamentary panel recommends expanding scope of price control to cover all medicines available in India

<a href="http://www.shutterstock.com/pic-228848833/stock-photo-pills-drug.html" target="_blank">Image</a> via Shutterstock
Press Trust of India New Delhi
Last Updated : Apr 20 2015 | 8:29 PM IST
Stating that all medicines are essential, a Parliamentary panel has recommended expanding the scope of price control to cover all medicines available in the country.

According to a report by the Standing Committee on Chemicals and Fertilisers tabled in Parliament today, all medicines, including life saving drugs, should be available in the market at affordable cost.

Currently, drug price regulator National Pharmaceutical Pricing Authority (NPPA) has fixed prices of 509 formulation packs based on National List of Essential Medicines.

Also Read

"The Committee was surprised to know that all medicines are not listed in the National List of Essential Medicines (NLEM). The committee are of the view that all medicines are essential and is taken only when it is needed by the patient," the report on Department of Pharmaceuticals said.

The panel further said: "All these medicines, including life saving drugs, should be available in the market at affordable cost. To keep this in view, the committee recommend that the scope of price control needs to be enlarged to make all the drugs available, especially life saving drugs, in all parts of the country."

The government should also expedite the process of notifying the ceiling prices of the remaining medicines in NLEM, it added.

Expressing concern over large sum of money spent on importing pharmaceutical products, the panel also called for incentivising domestic bulk drug industry and discourage Indian firms from buying from overseas.

It said Rs 17,944 crore was spent in 2013-14 to import medicinal and pharmaceutical products.

"The Committee are of the strong view that to realise the dream of 'Make in India' concept in pharmaceutical sector, the government should boost and incentivise domestic bulk drug industry and discourage Indian pharmaceutical firms from importing," it said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 20 2015 | 8:22 PM IST

Next Story